Foundry Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Foundry Partners’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-2,255	Closed	-$217K	–	296
2023 Q4	$217K	Buy	+2,255	New	+$199K	0.01%	279
2023 Q3	–	Sell	-3,188	Closed	-$276K	–	295
2023 Q2	$276K	Hold	3,188	–	–	0.02%	293
2023 Q1	$310K	Sell	3,188 -49	-2%	-$5.08K	0.02%	283
2022 Q4	$335K	Buy	3,237 +2	+0.1%	+$188	0.02%	259
2022 Q3	$274K	Buy	+3,235	New	+$288K	0.02%	290
2022 Q1	–	Sell	-2,401	Closed	-$212K	–	336
2021 Q4	$212K	Buy	+2,401	New	+$198K	0.01%	341
2021 Q3	–	Sell	-2,401	Closed	-$200K	–	368
2021 Q2	$200K	Buy	+2,401	New	+$190K	0.01%	367
2021 Q1	–	Sell	-2,401	Closed	-$211K	–	435
2020 Q4	$211K	Buy	+2,401	New	+$190K	0.01%	413
2020 Q3	–	Sell	-2,401	Closed	-$296K	–	417
2020 Q2	$296K	Buy	+2,401	New	+$239K	0.01%	364
2017 Q2	–	Sell	-3,158	Closed	-$277K	–	414
2017 Q1	$277K	Sell	3,158 -84	-3%	-$7.47K	0.01%	413
2016 Q4	$269K	Buy	+3,242	New	+$279K	0.01%	418

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Foundry Partners's BMRN Position: Q1 2024 in Review

Foundry Partners sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2024, closing a stake of 2,255 shares — an estimated $217K sold.

Foundry Partners first reported a position in BMRN in Q4 2016 and held it in 11 quarters. The position peaked at $335K in Q4 2022. 560 funds tracked by Wall St. Rank hold BMRN as of Q1 2024.

Foundry Partners reported no remaining BioMarin Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Foundry Partners sold 2,255 BioMarin Pharmaceuticals shares in Q1 2024, an estimated $217K.
Foundry Partners first reported a position in BioMarin Pharmaceuticals in Q4 2016 and held it in 11 quarters.
Foundry Partners's BioMarin Pharmaceuticals position peaked at $335K in Q4 2022.
560 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2024.

Based on Foundry Partners's 13F filing for Q1 2024, filed 8 May 2024.